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Abstract 28 
Kisspeptin signalling is indispensable for fertility, stimulating gonadotropin- releasing hormone (GnRH) 29 
secretion and mediating gonadal steroid feedback on GnRH neurons. Moreover, kisspeptin neurons have 30 
been implicated in other non-reproductive neuroendocrine roles. Kisspeptin appears to also regulate 31 
growth hormone secretion but much of the data appear contradictory. We sought to clarify a potential role 32 
of kisspeptin in GH regulation by examining the effect of kisspeptin antagonists on growth hormone (GH) 33 
secretion in ewes under various physiological conditions. Our data show clear and robust increases in GH 34 
secretion following lateral ventricle or third ventricle infusion of kisspeptin antagonists p-234 and p-271 35 
in either ovariectomised or anestrous ewes. Central infusion of kisspeptin-10 had no effect on GH 36 
secretion. To determine the level at which kisspeptin may influence GH secretion we examined 37 
expression of the cognate kisspeptin receptor, GPR54, in pituitary cells and showed by 38 
immunocytochemistry that the majority of somatotropes express GPR54 while expression was largely 39 
negative in other pituitary cells. Overall, we have demonstrated that blocking kisspeptin signalling by 40 
antagonists stimulates GH secretion in ewes and that this is likely mediated by inhibiting endogenous 41 
kisspeptin activation of GPR54 expressed on somatotropes. The findings suggest that endogenous 42 
kisspeptin inhibits growth hormone secretion through GPR54 expressed on somatotropes.  43 
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Introduction 44 
Kisspeptin and its cognate receptor GPR54 are now well accepted as a critical component of central 45 
nervous system regulation of GnRH neuron control of reproductive hormones (de Roux, et al. 2003; 46 
Seminara, et al. 2003; Topaloglu, et al. 2012).  Kisspeptin neuron activity is essential for the stimulation 47 
of GnRH secretion (Gottsch, et al. 2004; Han, et al. 2005) and mediates both negative and positive 48 
feedback regulation by gonadal steroid hormones onto GnRH neurons (Smith 2013) and kisspeptin 49 
signalling is required for the onset of puberty (Han et al. 2005). 50 
 51 
Leptin and products of metabolism also impact on kisspeptin neuron function and kisspeptin neurons are 52 
hypothesized to be “whole body sensors” linking physiological status to reproduction (Pineda, et al. 53 
2010a). Growth hormone (GH) plays a role in normal reproductive function (Hull and Harvey 2001, 54 
2002) and in metabolic regulation. A substantial number of studies have now reported effects of 55 
kisspeptin on GH secretion in various species, under different physiological conditions, using peripheral 56 
or central administration, and by examining direct effects on pituitary cells in culture (Foradori, et al. 57 
2017; Gutierrez-Pascual, et al. 2007; Kadokawa, et al. 2008; Kadokawa, et al. 2007; Lents, et al. 2008; 58 
Whitlock, et al. 2010; Whitlock, et al. 2008). Kisspeptin is a member of the large family of RF-amide 59 
peptides which target an equally large family of cognate receptors (Dockray 2004). Consequently doses 60 
and mode of administration of kisspeptin might have effects that are not mediated via the GPR54 cognate 61 
receptor but result from activation of other GPCRs (Oishi, et al. 2011), which may contribute to 62 
contradictory reports of kisspeptin effects on GH. 63 
 64 
In an attempt to clarify effects of kisspeptin on GH we have studied the effects of kisspeptin antagonists 65 
on GH secretion in ewes under various physiological conditions. Our data suggest that GH is under 66 
endogenous kisspeptin inhibition, which is relieved by kisspeptin antagonist treatment, resulting in an 67 
elevation of GH. 68 
 69 
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Materials and Methods 70 
Animals and Peptides 71 
All experimental procedures were conducted under a protocol approved by the Monash School of 72 
Biomedical Sciences Animal Ethics Committee. Adult Corriedale ewes were housed under natural 73 
lighting. Kisspeptin antagonist (peptide-234 and peptide-271) were synthesized by EZBiolab Inc. 74 
(Carmel, IN). 75 
The peptide sequence of peptide-234 is ac-(D-A)NWNGFG(D-W)RF-NH2 (Roseweir, et al. 2009). 76 
Peptide-271 is the same sequence as peptide-234 with the addition of a seven amino acid cationic cell-77 
penetrating peptide penetratin RRMKWKK extension at the NH2 terminus of peptide-234. This peptide 78 
was shown in vitro and in vivo in rats, mice, sheep and monkeys to be an effective kisspeptin antagonist 79 
(Albers-Wolthers, et al. 2017; De Bond, et al. 2013; Guerriero, et al. 2012; Millar, et al. 2010; Pineda, et 80 
al. 2010b; Roseweir et al. 2009; Roseweir and Millar 2013; Smith, et al. 2011).  81 
 82 
Kisspeptin peptide YNWNSFGLRY-NH2 corresponding to the murine C terminal Kiss1 decapeptide was 83 
obtained from Phoenix Pharmaceuticals Ltd. (Belmont, CA). This sequence is identical to the C-terminal 84 
sequence of ovine kisspeptin (GenBank accession No. DQ059506). 85 
 86 
Effect of kisspeptin antagonists on GH secretion in ewes 87 
Experiment 1: Effect of third ventricular infusion of peptide 234 on GH in ovariectomized ewes.  88 
Experiments were performed as described previously (Roseweir et al. 2009). Animals were bilaterally 89 
ovariectomized (OVX) at least one month before any experimental manipulations Permanent indwelling 90 
third cerebral ventricular (3V) cannulae were implanted in a subsequent surgical procedure as described 91 
previously (Barker-Gibb, et al. 1995). Approximately 2 weeks after 3 V surgery, one external jugular vein 92 
was cannulated for blood sampling and animals housed in single pens; cannulae were kept patent with 93 
heparinized saline. Ewes were assigned to treatment groups (n=4 per group); peptide 234 (diluted in 94 
aCSF; 150 mM NaCI, 1.2 mM CaCI2, I mM MgCI2, 2.8 mM KCI) or control (aCSF only). The following 95 
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day, infusion lines were connected to 3V cannulae, and blood sampling commenced at 7:00 am. Samples 96 
were collected every 10 min. After 3 h of sampling, peptide 234 (or control) was infused into the 3V at a 97 
dose of 40 µg/h for 1 h, with an initial dose of 10µg. Both peptide 234 and vehicle were infused at 200 98 
µl/h using Graseby MS16A infusion pumps (Smith Medical Australasia). After infusion, 3 V lines 99 
remained in place, and blood sampling continued for a further 2 h (total of 6 h). Plasma was harvested 100 
immediately from samples and frozen at -20
 
C until assayed. 101 
 102 
Experiment 2: Effect of lateral ventricular infusion of peptide 271 on GH in ovariectomized ewes. 103 
Experiments were performed as previously described (Smith et al. 2011). Ewes were bilaterally OVX as 104 
above and permanent indwelling lateral ventricle (LV) cannulae were implanted as described previously 105 
(Henry et al., 2008). Experiments procedures and blood sampling were similar to above ewes received 106 
either peptide 271 (1 h continuous infusion 300 µg/h, with an initial 200 µg/h loading dose; n=5) or 107 
vehicle (aCSF; n=5) into the LV (200 µg/h). After infusion, LV lines remained in place as blood sampling 108 
continued for 3 h. Plasma was harvested immediately and frozen at -20
◦
C until assayed. 109 
 110 
Experiment 3: Effect of long-term lateral ventricular infusion of peptide 271 on GH in ovary intact 111 
estrogen treated anestrous ewes.   112 
Experiments were performed as previously described (Smith et al. 2011), in order to determine the role of 113 
kisspeptin signalling in mediating the LH surge, hence a longer infusion period of kisspeptin antagonist 114 
was employed. LV and jugular vein cannulae were implanted (as above) in anestrous ewes. All ewes 115 
received an initial intramuscular (im) injection of 50 µg estradiol benzoate (Intervet, New South Wales, 116 
Australia) in 1 ml peanut oil. Blood sampling commenced 9 h later and samples (5 ml) were taken every 117 
10 min for 9 h, then every 30 min for a further 12h. After 3 h of blood sampling, ewes received LV 118 
infusions (200 µl/h) of kisspeptin antagonist (8 h continuous infusion 300 µg/h, with an initial 200 µg 119 
loading dose; n=6) or vehicle (aCSF; n=6). Plasma was harvested immediately and frozen at -20◦C until 120 
assayed. 121 
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 122 
Experiment 4: Effect of lateral ventricular infusion of kisspeptin-10 on GH secretion in ovary-intact 123 
anestrous ewes.  124 
Experiments were performed as previously described (Li, et al. 2015), in order to determine the role of 125 
kisspeptin in mediating the LH pulses. Ovary intact ewes during the southern hemisphere anestrus season 126 
(September) were prepared for LV and jugular vein cannulation (as above). Blood samples were collected 127 
every 10 min for 3 h then animals received kisspeptin (40 µg/h with an initial loading dose of 40 µg, n=6) 128 
or vehicle (aCSF, n=6) treatment for 4 h (200 µl/h). After the infusion, LV lines remained in place, and 129 
blood sampling continued for a further 2 h (total of 9 h). Plasma was harvested immediately from samples 130 
and frozen at -20
 
C until assayed. 131 
 132 
GH Radioimmunoassay 133 
Plasma samples from ewes were assayed in duplicate following the method of Thomas et al. (Thomas, et 134 
al. 1990) using the standard NIDDK-oGH-I-4 and NIDDK-anti-oGH-2 antiserum. The assay sensitivity 135 
was 1 ng/ml, the intra-assay CV was less than 10% between 4 and 51 ng/ml and the interassay CV was 136 
20%.  137 
 138 
Immunocytochemistry of GPR54 and pituitary hormones in ovine pituitary 139 
An antiserum (RM1211) to the carboxyl terminal sequence CVLGEDNAPL of human GPR54 conjugated 140 
to haemocyanin was raised in rabbits. The specificity of the highest titre antiserum was demonstrated by 141 
positive membrane staining in COS7 cells transfected with the human GPR54 pcDNA and an absence of 142 
staining in untransfected COS7 cells (data not shown). Pituitary glands from adult ewes were fixed in 143 
Bouin’s or 4% Neutral Buffered formaldehyde (4%NBF) and sections processed for 144 
immunocytochemistry using GPR54 antiserum and counter stained with hematoxylin. To determine 145 
which pituitary cell types expressed GPR54, dual staining was conducted with rabbit antisera raised 146 
against ovine prolactin, growth hormone, luteinizing hormone and adreno-corticotropic hormone 147 
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(supplied by the National Hormone and Pituitary Programme of NIDDK). Following dewaxing and 148 
rehydration of sections through graded ethanols endogenous peroxidase activity was blocked using 3% 149 
hydrogen peroxide in methanol, before blocking endogenous biotin using avidin/biotin block (Vector 150 
labs, UK). Sections were then incubated with rabbit anti GPR54 antiserum in 20% normal goat serum in 151 
Tris Buffered Saline (TBS). Binding was detected using goat anti rabbit biotinylated fab (Abcam, UK) 152 
and Streptavidin-HRP before visualising with Diaminobenzidine (DAB). Following a repeat of the 153 
avidin/blocking, sections were incubated with rabbit antiserum to either porcine ACTH, ovine GH, ovine 154 
LH-beta or ovine prolactin at NIDDK recommended dilutions.  Binding was detected using secondary 155 
biotinylated fab antibody (Abcam, UK) and Streptavidin-AP before visualising with fast blue (Abcam). 156 
 157 
Data Analysis 158 
All group data are presented as the mean ± SEM. Plasma GH concentrations in response to treatment over 159 
time were examined by repeated measures ANOVA. The effect of kisspeptin antagonist or kisspeptin 160 
treatment on GH was further examined by comparing the mean GH concentration in samples pre-infusion 161 
(0-180 min), during the infusion (Experiment 1 and 2, 180-240 min; Experiment 3, 180-720 min; 162 
Experiment 4, 180-420 min) and post infusion (Experiment 1, 240-360 min; Experiment 2, 240-420 min; 163 
Experiment 3, 720-1260 min; Experiment 4, 420-540 min). The mean GH values were calculated for each 164 
animal during the relevant time phase and used to generate group means. Data were assessed by repeated 165 
measures ANOVA.   166 
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Results 167 
Effect of kisspeptin antagonist on GH secretion in ewes 168 
Third ventricular administration of kisspeptin antagonist peptide-234 significantly increased the plasma 169 
concentration of GH in OVX ewes (Figure 1a). Mean GH was 3-fold greater during the peptide-234 170 
infusion compared to aCSF control (Figure 1b, P<0.005). Table 1 provides a summary of the effects of 171 
peptide-234 on GH and our previously published analysis of plasma LH, prolactin and cortisol in 172 
ovariectomised ewes (Roseweir et al. 2009).  173 
 174 
Lateral ventricular administration of peptide-271 resulted in similar effects (Figure 2a). Mean GH levels 175 
(Figure 2b) were again significantly elevated during the time of the antagonist infusion compared to 176 
vehicle controls (P<0.01). Previously, peptide-271 inhibited LH pulses and mean LH in ovariectomised 177 
ewes (Smith et al. 2011). 178 
 179 
Similar results were achieved with central peptide-271 treatment in ovary intact ewes (Figure 3a). Here, 180 
the mean GH concentration over the 8 h continuous peptide-271 infusion was significantly greater than 181 
during the aCSF infusion (P<0.001, Figure 3b). From our previous analysis, the peptide-271 kisspeptin 182 
antagonist in this paradigm significantly attenuated the estradiol-induced LH surge (Smith et al. 2011). 183 
 184 
Effect of kisspeptin-10 on GH secretion in ovary-intact anestrous ewes 185 
Lateral ventricular administration of kisspeptin-10 had no effect on plasma GH concentrations in ovary-186 
intact anestrous ewes (Figure 4a).  Mean GH concentration over the 4 h continuous infusion period was 187 
similar between kisspeptin-10 and control ewes (Figure 4b). In the same animals, there was a significant 188 
stimulation of LH (Li et al. 2015). 189 
 190 
Ovine somatotropes co-express kisspeptin receptor 191 
 192 
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Pituitaries from adult ewes displayed clear immunostaining with the GPR54 antiserum RM 1211 in both 193 
NBF (Fig 5E) and Bouins (Fig 5F) fixation. Staining was ablated by preincubation of the antiserum with 194 
the CVLGEDNAPL immunogen. (data not shown). Subsequent staining with rabbit antisera to prolactin, 195 
adreno-corticotropin, luteinizing hormone and growth hormone in Bouins clearly revealed the various cell 196 
types but staining of some of these hormones was not clear with NBF staining (data not shown). In the 197 
Bouins fixed tissue there was little or no co-localisation of staining (<1%) in corticotropes (Fig 5A), 198 
gonadotropes (Fig 5C), and lactotropes (<1%, Fig 5D), while the majority of somatotropes (86%, Fig 5B) 199 
stained positive for GPR54. 200 
 201 
Discussion 202 
Adequate GH secretion is required for optimal reproductive hormone production during puberty and in 203 
adulthood. Because GH is involved in metabolic regulation and recent evidence supports the concept that 204 
kisspeptin is an integrator of nutrition and metabolic regulation of reproduction (De Bond and Smith 205 
2014; Pineda et al. 2010a) it is plausible that kisspeptin may be a regulator of GH. A number of 206 
publications support this notion. Kisspeptin stimulated calcium influx in rat somatrotropes and secretion 207 
of GH from rat (Gutierrez-Pascual et al. 2007) and bovine (Kadokawa et al. 2007) pituitary cells. 208 
However, Jayasena et al (Jayasena, et al. 2014)  found no effect of kisspeptin on GH secretion from the 209 
pituitary in vitro. In vivo studies present a complexity of findings  including contradictory reports. High iv 210 
doses (3>nmol/kg) of kisspeptin stimulated prolonged GH release in prepubertal heifers (Kadokawa et al. 211 
2008) but a lower dose of kisspeptin had no effect in ovariectomised adult cows but stimulated GH when 212 
progesterone or estrogen or both were administered (Whitlock et al. 2008). Central or systemic 213 
administration of kisspeptin had no effect on GH in prepubertal female pigs while inducing LH secretion 214 
(Lents et al. 2008). Similarly kisspeptin peripheral infusion had no effect on GH in cows while robustly 215 
stimulating LH but preinfusion of kisspeptin reduced GH responses to GHRH and somatostatin 216 
withdrawal (Whitlock et al. 2010). This study also reported no GH response to iv kisspeptin in ewes but a 217 
small response when administered icv (Whitlock et al. 2010). However, recently published data show 218 
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kisspeptin can stimulate GH, but only in fasted ewes, by a ghrelin-NPY mediated mechanism (Foradori et 219 
al. 2017). These complex, and often, contradictory reports may be a result of the large family of RFamide 220 
receptors, which can be targeted by kisspeptin. We attempted to clarify the field by utilising specific 221 
antagonists to GPR54.  In our study we found no effect of administration of kisspeptin into the LV on GH 222 
secretion in intact ewes, which is in agreement with the reported lack of response to peripheral 223 
administration in intact cows studies (Whitlock et al. 2008) and prepubertal female pigs (Lents et al. 224 
2008) but contrasts with a small GH increase reported in ewes (Whitlock et al. 2010) although the 225 
immediate nutritional status may be key in this model (Foradori et al. 2017). In women, both acute and 226 
chronic peripheral administration of kisspeptin-54 failed to alter GH concentrations (Jayasena et al. 227 
2014). As mentioned above, these varying and contradictory reports on the effects of kisspeptin on GH 228 
may be the result of cross signalling through the large family of RFamide receptors, especially when high 229 
doses are administered centrally. For example we have observed that kisspeptin has a high affinity for the 230 
GnIH receptor, GPR147, while GnIH binds poorly to GPR54 (Millar RP, unpublished data). In the same 231 
study peptide-234 and peptide-271 did not bind to GPR147 suggesting that they do not interact with other 232 
RFamide receptors and are better probes for determining the role of kisspeptin in GH secretion. 233 
 234 
We have therefore attempted to reconcile these apparently conflicting effects of kisspeptin on GH by 235 
administering kisspeptin antagonists in ovariectomised and estrogen treated anestrous ewes. Robust 236 
increases in GH were observed in three separate and different experiments after administration of either 237 
antagonist peptide-234 or antagonist peptide-271. Moreover, GH was increased regardless of site of 238 
administration (3V or LV) and the nature of the antagonist: peptide-271, which has the penetratin 239 
sequence attached at the NH2 terminus, designed to be cell-permeant, or non-cell-permeant peptide-234). 240 
For each experiment, ovariectomy or estradiol treatment increased LH pulse and surge dynamics 241 
(respectively) and kisspeptin antagonist inhibited plasma LH concentrations but had no effect on cortisol 242 
or prolactin (Roseweir et al. 2009; Smith et al. 2011). Thus, the effects are highly specific for GH increase 243 
and LH decrease without affecting other pituitary hormones (see Table 1.). The timing of each effect (GH 244 
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versus LH) appears, however, to differ, with the relatively delayed effect on LH being due to a time delay 245 
in the antagonists having first to compete out endogenous kisspeptin, which then results in a decrease in 246 
GnRH followed by a decrease in LH. In contrast, the effect on GH appears much more acute, possibly 247 
due to the more direct and immediate effect on the pituitary somatotrope expressing GPR54 receptors.  248 
 249 
The stimulation of GH by both kisspeptin antagonists suggests that endogenous kisspeptin is restraining 250 
GH secretion in the ewe models we studied. This might be at a hypothalamic level through inhibiting 251 
GHRH or stimulating somatostatin as suggested by Whitlock et al (Whitlock et al. 2010), or directly at 252 
the pituitary level on somotatropes or through other pituitary cell types that affect the somatotrope. To 253 
address the site of kisspeptin action we examined the expression of GPR54 in ewe pituitary cell types 254 
using a highly specific antiserum to GPR54. GPR54 was almost exclusively expressed in somatotropes 255 
and was virtually absent in LH positive gonadotropes, prolactin positive lactotropes or ACTH positive 256 
corticotropes. This expression of GPR54 on somatotropes therefore provides a potential mechanism for 257 
the kisspeptin and antagonist effects on GH. GPR54 mRNA expression has been previously reported in 258 
dispersed sheep pituitary mainly in somatotropes, with lower expression in enriched lactotropes and 259 
gonadotropes (Smith, et al. 2008) but GPR54 protein was not examined as in this study, which showed 260 
expression of protein predominantly in somatotropes.  261 
 262 
The sources of kisspeptin, which may target GPR54 in somatotropes are potentially through hypothalamic 263 
kisspeptin secretion into the portal system or from peripheral tissues via the systemic circulation or 264 
through local pituitary cell production. Systemic and portal sources are unlikely because kisspeptin in 265 
hypophyseal portal  blood in ewes (which is the sum of hypothalamic secretion and systemic levels) is 266 
very low with a maximum of 12 pg/ml (Smith et al. 2008). This equates to about 10 pM for Kp-10 and 2 267 
pM for Kp-54. This level is too low for effective receptor occupancy as the affinity (ie 50% receptor 268 
occupancy) of GPR54 for kisspeptin is about 1-5 nM (Roseweir et al. 2009) – about 1000 times higher. 269 
This indicates that GH stimulation is not from hypothalamic kisspeptin targeting somatotropes via the 270 
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portal system or from the general circulation.  Expression of kisspeptin has been reported in the pituitary 271 
gland of mammalian species (Gutierrez-Pascual et al. 2007; Kotani, et al. 2001; Muir, et al. 2001; 272 
Quennell, et al. 2010; Richard, et al. 2008) and in some instances localised to specific pituitary cell types 273 
such as corticotropes in the rhesus monkey (Ramaswamy, et al. 2009), gonadotropes in the rat (Richard et 274 
al. 2008) and to enriched somotatropes, lactotropes and gonadotropes in ewes (Smith et al. 2008). This 275 
therefore suggests that local pituitary kisspeptin production inhibits somatotrope secretion of GH, which 276 
is ablated by the antagonists to increase GH.  277 
 278 
The demonstration in this study of a virtual absence of GPR54 in gonadotropes in the ewe indicates that 279 
previous reports on kisspeptin stimulation of LH secretion from the ewe pituitary in vitro (Smith et al. 280 
2008) are unlikely to be mediated via GPR54 in gonadotropes and are most likely to be indirectly through 281 
somatotropes or nonspecific on related RFamine receptors. Importantly, the effect of kisspeptin and/or 282 
kisspeptin antagonists on GH release from sheep pituitary primary cultures or cultured somatotropes has 283 
not (to our knowledge) been studied. Our demonstration of high expression of GPR54 in somatotropes 284 
suggests a possibility that they might secrete activators of gonadotropes to account for the observation of 285 
kisspeptin stimulation of LH in the pituitary. It is also feasible that since relatively high doses of 286 
kisspeptin were required to stimulate LH from the pituitary in the studies by Witham et al. (Witham, et al. 287 
2013) (100nM) and Gutierrez-Pascual et al. (Gutierrez-Pascual et al. 2007) (10-100nM), the effect may be 288 
through kisspeptin activation of other RFamide receptors. Studies using kisspeptin antagonists may 289 
clarify this. However the demonstration that kisspeptin at doses that stimulate LH in intact ewes do not 290 
stimulate LH when administered to hypothalamic-pituitary-disconnected ewes (Smith et al. 2008) suggest  291 
that although kisspeptin can stimulate LH secretion from the pituitary in vitro it does not play a 292 
significant role in the direct stimulation of the gonadotrope in the ewe in vivo. 293 
 294 
In summary, we have demonstrated that two kisspeptin antagonists administered into the LV or 3V 295 
robustly stimulate GH in ovariectomised and estrogen-treated anestrous ewes. The kisspeptin receptor 296 
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GPR54 is expressed in the majority of somatotropes suggesting that endogenous kisspeptin binds to these 297 
receptors and inhibits GH secretion such that kisspeptin antagonists elevate growth hormone. These 298 
findings lay the foundation for more in depth study on the precise physiological relationships between the 299 
reproductive and GH systems and the possibility of developing kisspeptin antagonists as therapeutics for 300 
GH stimulation. 301 
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Figure Legends 1 
Figure 1. Third ventricle infusion of kisspeptin antagonist (KA p-234) stimulatesd the 2 
secretion of GH in OVX ewes. A, Mean concentrations of GH are shown in ewes treated with 3 
kisspeptin antagonist (closed squares) or aCSF (open circles). The infusion period is 4 
represented by the closed bar. B, Mean GH pre-, during the infusion, and post-infusion (n=4 5 
per group). A significantly elevated mean GH concentration the during kisspeptin antagonist 6 
infusion was detected. Data are the mean+SEM. ***, P 0.001 7 
 8 
Figure 2.  Lateral ventricle infusion of kisspeptin antagonist (KA p-271) stimulated the 9 
secretion of GH in OVX ewes. A, Mean concentrations of GH are shown in ewes treated with 10 
kisspeptin antagonist (closed squares) or aCSF (open circles). The infusion period is 11 
represented by the closed bar. B, Mean GH pre-, during the infusion, and post-infusion (n=5 12 
per group). A significantly elevated mean GH concentration the during kisspeptin antagonist 13 
infusion was detected. Data are the mean+SEM. **, P 0.01 14 
 15 
Figure 3.  Long term (8 h) lateral ventricle infusion of kisspeptin antagonist (KA p-271) 16 
stimulated the secretion of GH in intact anestrus ewes. A, Mean concentrations of GH are 17 
shown in ewes treated with kisspeptin antagonist (closed squares) or aCSF (open circles). 18 
The infusion period is represented by the closed bar. B, Mean GH pre-, during the infusion, 19 
and post-infusion (n=6 per group). A significantly elevated mean GH concentration the 20 
during kisspeptin antagonist infusion was detected. Data are the mean+SEM. ***, P 0.001 21 
 22 
Figure 4. Central infusion of kisspeptin had no effect on secretory pulses of GH in ewes. A, 23 
Concentrations of GH are shown in ewes treated with kisspeptin or aCSF (vehicle). The 24 
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 2
infusion period is represented by the closed bar. B, Mean GH pre-, during the infusion, and 25 
post-infusion (n = 6 per group). Data are mean+SEM. 26 
 27 
Figure 5. Representative photomicrographs showing immunohistochemical localisation of 28 
GPR54 (brown) in the adult ewe pituitary.  Immunostaining with rabbit antisera to adreno-29 
corticotropin (A, ACTH + GPR54), growth hormone (B, GH + GPR54), luteinizing hormone 30 
(C, LH + GPR54) and prolactin (D, PRl + GPR54) revealed the various cell types (blue). The 31 
majority of somatotropes (86%) stained positive for GPR54 (B). E and F show GPR54 32 
staining in pituitary sections fixed with 4% Neutral Buffered formaldehyde (E; 205-0198 33 
NBF) or Bouins (F; 2005-200 Bouins) and counter stained with hematoxylin (blue). Scale 34 
bar, 100 µm. 35 
 36 
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Table 1. 
 
 Control Peptide-234 P Value 
Mean GH (ng/ml)    
Pre Infusion 3.99 ± 1.33 4.42 ± 1.33 0.84 
Infusion 4.49 ± 1.49 14.36 ± 2.15 <0.005 
Post Infusion 5.93 ± 1.20 8.94 ± 1.13 0.11 
Mean LH (ng/ml)*    
Pre Infusion 2.70 ± 0.34 2.73 ± 0.43 0.96 
Infusion 2.44 ± 0.25 2.89 ± 0.55 0.50 
Post Infusion 2.60 ± 0.11 1.78 ± 0.34 <0.05 
Mean prolactin (ng/ml)*    
Pre Infusion 27.89 ± 9.21 58.67 ± 14.59 0.12 
Infusion 17.02 ± 7.34 44.91 ± 15.87 0.16 
Post Infusion 5.58 ± 3.23 27.74 ± 9.23 0.06 
Mean cortisol (ng/ml)*    
Pre Infusion 11.90 ± 2.79 8.08 ± 1.96 0.31 
Infusion 8.51 ± 1.81 8.26 ± 1.55 0.92 
Post Infusion 11.57 ± 2.00 18.45 ± 5.98 0.32 
 
Table 1. Summary of plasma GH, LH, prolactin and cortisol from Experiment 1.  
* data derived from experiments in Roseweir et al. (Roseweir et al. 2009). 
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